MIN4ALD SIGNED
Use of MIN-102 for the treatment of children with cerebral ALD
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0MIN4ALD project word cloud
Explore the words cloud of the MIN4ALD project. It provides you a very rough idea of what is the project "MIN4ALD" about.
Project "MIN4ALD" data sheet
The following table provides information about the project.
| Coordinator |
MINORYX THERAPEUTICS S.L.
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 4˙437˙500 € |
| EC max contribution | 3˙106˙250 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-10-01 to 2021-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | MINORYX THERAPEUTICS S.L. | ES (MATARO BARCELONA) | coordinator | 3˙106˙250.00 |
Map
Project objective
The objective of the MIN4ALD project is the development of a new pharmacological therapy to treat paediatric patients with cerebral ALD (cALD) - the most rapidly progressive and devastating phenotype of X-ALD (X-linked adrenoleukodystrophy).
cALD is a rare, fatal genetic disorder that affects nerve cells in the brain. Symptoms of cALD usually occur in a boy’s early childhood, and are characterized by rapidly progressive loss of visual, auditory, motor and cognitive function, with death usually occurring after 2 to 4 years from disease onset.
Currently, there is no pharmacological treatment available on the market. The only existing alternative for cALD patients is hematopoietic stem cell transplantation, yet the procedure itself is very aggressive and results are not always optimal.
Minoryx has developed a candidate drug that has demonstrated in several studies an excellent potential to treat patients with X-ALD. MIN4ALD Phase 2 demonstration is key to bring this unique treatment to the market. The results obtained in the Feasibility Analysis carried out indicated that MIN4ALD could be a huge business opportunity within the orphan diseases market.
The Global orphan diseases market is a niche market valued at US$ 121.6 billion in 2015. It is expected to grow to US$ 576.9 billion by 2022, with an average CAGR of 24.9% during the period 2015-2022. This is an impressive growth compared to the Global pharma market, which projects a 6.3% CAGR through 2022.
Minoryx has raised an important funding amount for R&D development from leading investors and has the support of reference Key Opinion Leaders. Minoryx received Orphan Drug Designation from both EU and FDA and holds a patent application covering the use of MIN-102 for X-ALD and other diseases affecting the central nervous system.
MIN4ALD will suppose a crucial stimulus for Minoryx to expand internationally and improve time-to-market, leading to the consolidation of the company in the pharmaceutical market.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIN4ALD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MIN4ALD" are provided by the European Opendata Portal: CORDIS opendata.